Abstract
Prescribing for refractive errors in infants and young children often presents a greater challenge to the optometrist than in the case of older children and adults. However, spectacle prescribing takes on a very important role in this age group since it can impact visual development. On the one hand, spectacle treatment when properly prescribed can reduce the risk of strabismus and amblyopia and enhance visual development. However, on the other hand, overly aggressive spectacle treatment may impair self-correcting processes (emmetropization) serving to reduce refractive error in the early years of life. Proper prescribing for infants and children must be rooted in an evidence-based approach. This article identifies the current evidence from basic research in ocular development as well as the results from clinical trials pertaining to the outcomes of early spectacle interventions. From this evidence, age specific guidelines are developed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
